During the past decade, Clinica Universidad de Navarra conducted 446 clinical trials. In the 10-year time frame, 446 clinical trials started and 110 clinical trials were completed, i.e. on average, 24.7% percent of trials that started reached the finish line to date. In the past 5 years, 246 clinical trials started and 88 clinical trials were completed. i.e. 35.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Clinica Universidad de Navarra" #1 sponsor was "Clinica Universidad de Navarra, Universidad de Navarra" with 46 trials, followed by "Janssen Research & Development, LLC" with 43 trials sponsored, "PETHEMA Foundation" with 35 trials sponsored, "Celgene" with 29 trials sponsored and "Hoffmann-La Roche" with 29 trials sponsored. Other sponsors include 453 different institutions and companies that sponsored additional 257 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Clinica Universidad de Navarra" #1 collaborator was "Bristol-Myers Squibb" with 10 trials as a collaborator, "Clinica Universidad de Navarra, Universidad de Navarra" with 8 trials as a collaborator, "Merck Sharp & Dohme LLC" with 7 trials as a collaborator, "BioNTech SE" with 6 trials as a collaborator and "Instituto de Salud Carlos III" with 6 trials as a collaborator. Other collaborators include 295 different institutions and companies that were collaborators in the rest 214 trials.

According to Clinical.Site data, the most researched conditions in "Clinica Universidad de Navarra" are "Multiple Myeloma" (61 trials), "Neoplasms" (11 trials), "Breast Cancer" (10 trials), "Melanoma" (10 trials) and "Acute Myeloid Leukemia" (9 trials). Many other conditions were trialed in "Clinica Universidad de Navarra" in a lesser frequency.

Most popular intervention types in "Clinica Universidad de Navarra" are "Drug" (480 trials), "Biological" (55 trials), "Device" (46 trials), "Other" (46 trials) and "Procedure" (29 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (80 trials), "Dexamethasone" (40 trials), "Bortezomib" (21 trials), "Daratumumab" (20 trials) and "Lenalidomide" (18 trials). Other intervention names were less common.

The vast majority of trials in "Clinica Universidad de Navarra" are 604 trials for "All" genders, 23 trials for "Female" genders and 13 trials for "Male" genders.

Currently, there are 272 active trials in "Clinica Universidad de Navarra". 5 are not yet recruiting, 165 are recruiting, 100 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 271 completed trials in Clinica Universidad de Navarra, 4 suspended trials, and 56 terminated clinical trials to date.

Out of the total trials that were conducted in Clinica Universidad de Navarra, 133 "Phase 1" clinical trials were conducted, 236 "Phase 2" clinical trials and 188 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 29 trials, and there were also 28 trials that are defined as “Not Applicable".

Clinica Universidad de Navarra has several departments that took part in Clinical trials: "Clinica Universidad de Navarra Madrid; Servicio de Oncología" - 14 trials, "Clinica Universitaria de Navarra; Servicio de Oftalmologia" - 10 trials, "Clinica Universitaria de Navarra; Servicio de Neurología" - 7 trials, "Clinica Universitaria de Navarra; Servicio de Oncologia" - 39 trials, "Clínica Universidad de Navarra (CUN) - Sede Madrid- Servicio de Neurología -" - 4 trials, "Clinica Universitaria de Navarra; Servicio de Hematologia" - 2 trials, "Clinica Universitaria de Navarra; Servicio de Hepatologia" - 2 trials, "Clinica Universitaria de Navarra Fase 4. Segunda planta, Consulta de Pediatria" - 2 trials, "Clinica Universitaria de Navarra; Servicio de Dermatologia" - 2 trials